Diabetes Mellitus

Metabolic·MeSH: Diabetes Mellitus

Prevalence

10700.0 / 100K

Incidence

600.0 / 100K/yr

112 drugs in development·38 companies·21 clinical trials

Drug Pipeline by Phase

Phase 3(31)
DrugCompany
AbataceptCidara Therapeutics, Inc. (CDTX)
afrezzaMANNKIND CORP (MNKD)
AZD6793ASTRAZENECA PLC (AZN)
BYDUREONENANTA PHARMACEUTICALS INC (ENTA)
cadisegliatinvTv Therapeutics Inc. (VTVT)
cadisegliatin 800 mg bidvTv Therapeutics Inc. (VTVT)
cadisegliatin 800 mg qdvTv Therapeutics Inc. (VTVT)
cagrisemaNovo Nordisk A/S (NVO)
DulaglutideELI LILLY & Co (LLY)
EmpagliflozinELI LILLY & Co (LLY)
faster-acting insulin aspartNovo Nordisk A/S (NVO)
icosemaNovo Nordisk A/S (NVO)
idegaspSanofi (SNY)
idegliraNovo Nordisk A/S (NVO)
insulin degludecNovo Nordisk A/S (NVO)
insulin glargineNovo Nordisk A/S (NVO)
insulin glargine/lixisenatideSanofi (SNY)
insulin icodecNovo Nordisk A/S (NVO)
insuline glargine u100Novo Nordisk A/S (NVO)
MK-2828Merck & Co., Inc. (MRK)
ormd-0801ORAMED PHARMACEUTICALS INC. (ORMP)
prochymalMesoblast Limited (MESO)
prochymalMesoblast Limited (MESO)
rapid-acting insulin analogMANNKIND CORP (MNKD)
SemaglutideELI LILLY & Co (LLY)
semaglutide bNovo Nordisk A/S (NVO)
semaglutide jNovo Nordisk A/S (NVO)
sglt2 inhibitorSanofi (SNY)
teplizumabSanofi (SNY)
TeplizumabSanofi (SNY)
vx-880VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 1(24)
DrugCompany
AGTX-2004 (DBPR211)Agentix Corp. (AGTX)
amg 127AMGEN INC (AMGN)
cagrilintideNovo Nordisk A/S (NVO)
dasiglucagonNovo Nordisk A/S (NVO)
degludec ivELI LILLY & Co (LLY)
degludec scELI LILLY & Co (LLY)
faster aspartNovo Nordisk A/S (NVO)
insulin aspartNovo Nordisk A/S (NVO)
insulin detemirNovo Nordisk A/S (NVO)
levonorgestrel + ethinylestradiolNovo Nordisk A/S (NVO)
lispro scELI LILLY & Co (LLY)
LY3209590ELI LILLY & Co (LLY)
ly3502970ELI LILLY & Co (LLY)
ly4057996 ivELI LILLY & Co (LLY)
ly4057996 scELI LILLY & Co (LLY)
nnc0363-1063Novo Nordisk A/S (NVO)
nnc0471-0119 hNovo Nordisk A/S (NVO)
nnc0519-0130Novo Nordisk A/S (NVO)
novo rapidNovo Nordisk A/S (NVO)
paracetamolNovo Nordisk A/S (NVO)
pre-study basal insulin scELI LILLY & Co (LLY)
pyroglutamate rongliflozinSUNSHINE BIOPHARMA INC. (SBFM)
RO7204239Crinetics Pharmaceuticals, Inc. (CRNX)
up421Sana Biotechnology, Inc. (SANA)
Unknown(1)
DrugCompany
xultophyNovo Nordisk A/S (NVO)
Phase 1/Phase 2(1)
DrugCompany
ALN-KHKALNYLAM PHARMACEUTICALS, INC. (ALNY)

Compare drugs

exenatide synthetic vs inpefaexenatide synthetic vs kirstyexenatide synthetic vs linagliptin

Frequently asked questions

How many drugs are in development for Diabetes Mellitus?

BioSniper tracks 112 drugs in development for Diabetes Mellitus across 38 companies.

How many clinical trials target Diabetes Mellitus?

There are 21 clinical trials targeting Diabetes Mellitus tracked by BioSniper.

What is the prevalence of Diabetes Mellitus?

The estimated prevalence of Diabetes Mellitus is approximately 10700.0 per 100,000 population.

Deep-dive into Diabetes Mellitus

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis